Development of HBsAg-Binding Aptamers that bind HepG2.2.15 cells via HBV surface antigen[*]

Jia LIU [1], Yan YANG [2**], Bin HU [1], Zhi-yong MA [1], Hong-ping HUANG [2], Yuan YU [2], Shen-pei LIU [2], Meng-ji LU [3,4] and Dong-liang YANG [1,2]

(1. Division of Clinical Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; 2. Experimental Medicine Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; 3. Department of Microbiology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; 4. Institute of Virology, Medical School of Duisburg-Essen University, Essen, 45122, Germany)

Abstract: Hepatitis B virus surface antigen (HBsAg), a specific antigen on the membrane of Hepatitis B virus (HBV)-infected cells, provides a perfect target for therapeutic drugs. The development of reagents with high affinity and specificity to the HBsAg is of great significance to the early-stage diagnosis and treatment of HBV infection. Herein, we report the selection of RNA aptamers that can specifically bind to HBsAg protein and HBsAg-positive hepatocytes. One high affinity aptamer, HBs-A22, was isolated from an initial 115 mer library of ~1.1×10^{15} random-sequence RNA molecules using the SELEX procedure. The selected aptamer HBs-A22 bound specifically to hepatoma cell line HepG2.2.15 that expresses HBsAg but did not bind to HBsAg-devoid HepG2 cells. This is the first reported RNA aptamer which could bind to a HBV specific antigen. This newly isolated aptamer could be modified to deliver imaging, diagnostic, and therapeutic agents targeted at HBV-infected cells.

Key words: Aptamer; Systematic evolution of ligands by exponential enrichment (SELEX); Hepatitis B virus (HBV); HBsAg; Hepatocytes

Hepatitis B virus (HBV) infection is one of the most prevalent chronic viral infections of humans, with there being approximately 300 million chronic carriers worldwide. Chronic infection can have serious consequences, including cirrhosis and hepatocellular carcinoma, and results in at least one million annual deaths[17, 21, 37]. The most commonly used drugs, interferon-α and nucleoside analogues have only a limited response and none is capable of completely eradicating the virus [10, 18, 24, 27].

Targeted delivery of therapeutic drugs to HBV-infected cells should increase the therapeutic index, reduce the concentration of drug required, and minimize

potential side effects [7, 9]. As hepatitis B virus surface antigen (HBsAg) is a common antigen on the surface of HBV-infected hepatocytes, it provides a perfect target for drug delivery [4, 16, 22, 30, 32].

Whereas antibodies have the ability to recognize HBsAg with high specificity and affinity, their large sizes and immunogenicity often limit their pharmacological significance. Humanized antibodies, antibody fragments, and short peptides show great promises but are still restricted by peptidase susceptibility and the immune response. The recent development of the SELEX (systematic evolution of ligands by exponential enrichment) process has provided a new alternative, yielding nuclease-resistant oligonucleotides that can be selected to bind tightly and specifically to a given ligand [2, 8, 34]. The diversity of structures exhibited by an aptamer library allows selection of tight binding aptamers for simple targets, such as a single amino acid [6], or for complex targets such as tumor cell lines [11]. Such oligonucleotides, termed "aptamers," have been made against over 150 different ligands and are emerging as a new class of molecules that contest antibodies in therapeutics, imaging, and diagnostics [12, 13].

Herein, we report the selection of RNA aptamers that can specifically bind to the HBsAg protein. One high affinity aptamer, termed HBs-A22, was isolated from an initial 115 mer library of $\sim1.1\times10^{15}$ random-sequence RNA molecules using the SELEX procedure. For further application, the binding activity of aptamer HBs-A22 to HBsAg-positive cells were also evaluated.

MATERIALS AND METHODS

Materials

The initial RNA library, designated as 25N, was synthesized by Sigma-Genosys Ltd. Unless otherwise noted, all chemicals were purchased from Sigma-Aldrich, all restriction enzymes were obtained from the TaKaRa Biotechnology Co. Ltd., and all cell culture products were purchased from Gibco BRL/Life Technologies, a division of Invitrogen. HBsAg ELISA Kits were purchased from the SINO-American Biotechnology Company. Purified HBsAg protein was generously provided by the Wuhan Institute of Biological Products.

Cell culture

HepG2 cells were grown in DMEM/High supplemented with 10% fetal bovine serum. HepG2.2.15 cells were grown in DMEM/High supplemented with 10% fetal bovine serum and 500μmol/L G418. All cell lines were grown in an incubator at 37℃ with an H_2O-saturated 95% air-5% CO_2 atmosphere. Cells were subcultured (Trypsin-EDTA) at ratios of not less than 1 to 3, and were grown in 35-mm plastic dishes for 1d prior to most experiments.

SDS-PAGE and Silver stain

Purified HBsAg protein was separated by 12% SDS-polyacrylamide gel electrophoresis (PAGE) and stained using a Silver Stain Plus kit (Bio-Rad Laboratories, Hercules, CA).

In vitro selection

Repeated rounds of aptamer selection and amplification were performed as described previously [33]. In brief, the oligonucleotide template was synthesized as a single-stranded 115-mer with the sequence5'-<u>TTAATACGACTCACTATAG</u>TTGATTGCGTGTCAATCATGG-25N-GGTCATGTGTATGTTGGGGATTAGGACCTGATTGAGTTCAGCCCACATAC-3', where the central 25N represents random oligonucleotides based on equal incorporation of A, G, C, and

T at each position; the sequence of the T7 polymerase promoter was underlined. The dsDNA molecules were generated by PCR amplification using primer 1 (5'-TTAATACGACTCACTATAGTTGATTGCGTGTCAATC-3') and primer 2 (5'-GTATGTGGGCTGAACTCAAT-3'). The initial RNA random library was prepared by T7 *in vitro* transcription at 37℃ for 4-16 h in a 50μL reaction mixture (0.5 to 1μg DNA, 5μL 10×transcription buffer, 400μg/μL PEG, 0.5mol/L MgCl$_2$, 100U/mL IPP, 50 U RNasin, 2.5mmol/L CTP, 2.5mmol/L UTP, 2.5mmol/L ATP, 2.5mmol/L GTP, and 0.36μg/μL T7 RNA polymerase). Products were then treated with 10 units of DNase I for 30 min at 37℃ and stopped with EDTA to 20 mmol/L. Products were separated by 6 mol/L urea/8% PAGE, excised, purified, quantitated, and diluted into 1×binding buffer (20mmol/L Tris-Cl, pH8.0, 80 mmol/L Kac, 10% glycerol, 1mmol/L MgCl$_2$, 0.2mmol/L EDTA, 10μmol/L. DTT).

Prior to each cycle, the RNA pool was passed through a HAWP filter (Millipore) pre-wetted with 1×binding buffer to remove potential filter-binding sequences. Pre-filtered RNA pool (final concentration to 300nmol/L) and HBsAg protein (final concentration to 30nmol/L) were mixed and the binding reaction was allowed to equilibrate for 40 min at 37℃ (1× binding buffer, 800μL final volume). The mixture was filtered through a HAWP filter pre-wetted with 1×binding buffer and rinsed with 5 mL 1×binding buffer. The filter membrane was then cut into small pieces and boiled in 200μL of elution buffer (7mol/L urea, 0.5mol/L ammonium acetate, 1mmol/L EDTA, 0.2% SDS) for 5 min. After a quick centrifugation, the supernatant was transferred to a fresh tube, and RNA was precipitated by adding 2.5 volume ethanol and 0.1 volume sodium acetate (pH 5.4). After being washed

with 75% ethanol, RNA was redissolved in 20μL DEPC treated water.

After reverse transcription (RT)-PCR amplification with primer 1 and primer 2, the resulting DNA was transcribed with T7 RNA polymerase for 4-16h at 37℃ in a 50μL reaction mixture and the product was purified as described above. This purified RNA pool was used in the next round of selection.

Cloning and sequencing

After twelve rounds of selection, RT-PCR products were cloned into pMD19-T plasmid. The bank was transformed into *E. coli* DH5α. 24 clones were picked randomly, and plasmids were isolated from these clones, purified, and analyzed by sequencing.

Predicting RNA secondary structure

RNA Structure Program version 4.6 (http://rna.urmc.rochester.edu/) was used to predict the secondary structures of aptamers from round 12. The most stable structures with the lowest free energies for each RNA oligo were compared.

^{32}P Labeling of RNA

RNAs were dephosphorylated by using alkaline phosphatase of calf intestine (New England Biolabs). After phenol extraction, dephosphorylated RNAs were 5'-termini labeled with [γ-^{32}P] ATP by using T4 Polynucleotide Kinase (TaKaRa Biotechnology Co. Ltd.). All reactions were carried out according to the manufacturer's instructions for these enzymes.

Nitrocellulose filter-binding assay

10 nmol of ^{32}P-labeled RNAs were allowed to equilibrate with an excess of protein HBsAg at 37℃ for 40 min. Samples were then filtered through a HAWP filter pre-wetted with 1×binding buffer and immediately rinsed with 5mL of the 1×binding buffer. The filter membranes were dried and counted by

scintillation counting (Perkin-Elmer Micro Beta JET 1450LSC lumiscence counter).

Gel mobility shift assay

Radiolabeled RNAs were mixed with protein HBsAg in 1×binding buffer and incubated at 37℃ for 40min. The mixtures were then loaded onto a 6% native PAGE gel and electrophoresed in 0.5×TBE buffer at 120V of constant voltage for 2h. The gel was directly analyzed using a Phosphorimager.

***In vitro* transcriptions**

In vitro transcription was set up with or without 10mmol/L FITC-labeled UTP. The following was applied for a 50μL transcription reaction: 0.5 to 1 μg DNA template, 5μL 10×transcription buffer, 400μg/μL PEG, 0.5mol/L $MgCl_2$, 100U/mL IPP, 50U RNasin, 2.5mmol/L 2F'-CTP, 2.5mmol/L 2F'-UTP, 2.5mmol/L ATP, 2.5 mmol/L GTP, and 0.36μg/μL T7 RNA polymerase, and treated water to obtain 50μL.

HBsAg reactivity assay

RNA pools of different rounds or aptamers from the final round pool were incubated with purified HBsAg protein in different molar ratio (10:1 or 100:1) at 37℃ for 30 min individually, the inhibition of the HBsAg reactivity by RNAs were then evaluated by enzyme-linked immunosorbent assay (ELISA). The detection of HBsAg by the commercial HBsAg ELISA kit was performed according to the manufacturer's instruction.

Fluorescent staining

HepG2 and HepG2.2.15 cells were plated at a density of $1.0×10^5$ cells/well or $1.5×10^5$ cells/well respectively, for a 24-well plate one day prior to experiment. For the binding experiment, cells were fixed in 50% methanol for 15 min at 4℃ and dried at room temperature, stained with 50nmol/L FITC-labeled aptamer in PBS for 20 min at room temperature, and washed in PBS. All cells were imaged with Olympus IX70 Inverted Fluorescence Microscope and CoolSnap CF camera (Photometrics, Roper Scientific). Images were equally processed in Adobe PhotoShop (Adobe Systems Inc.) to increase brightness and contrast.

RESULTS

Verification of HBsAg protein

The HBsAg protein was found to be 95% pure according to the silver staining results which consisted of a single band of correct molecular weight (Fig. 1). The specificity of the protein was also confirmed by commercial HBsAg ELISA Kit.

HBsAg SELEX

Considering that aptamers would be applicable under some expected physiological conditions, they were selected to bind to HBsAg at 37℃ (pH 7.4) to approach *in vivo* conditions. A library of $~1.1×10^{15}$ random-sequence RNA molecules was generated by *in vitro* transcription of a synthetic template and incubated for 40 min with purified HBsAg protein. Protein-nucleic acid complexes were isolated by filtration through a HAWP filter. The protein-bound

Fig. 1. Verification of HBsAg protein. Purified H1 was separated by SDS-PAGE and silver stained. Lane 1, protein marker; Lane 2, purified HBsAg.

RNA was then eluted and amplified by RT-PCR. The products of PCR amplification were then used as templates for *in vitro* transcription, generating a new pool of RNA enriched for HBsAg binding (Fig. 2A and 2B). Twelve rounds of selection and amplification were

performed, and the ability of enriched RNAs to bind to HBsAg was monitored by nitrocellulose filter- binding assays (Fig. 2C) and gel mobility shift assay (Fig. 2D).

Predicting Secondary Structures of Aptamers

Round 12 RNAs were amplified by RT-PCR and

Fig. 2. *In vitro* selection of HBsAg binding aptamers. A: Schematic of HBsAg *in vitro* selection. Repeated rounds of target binding, nitrocellulose filter selection, and amplification drove the evolution of the random sequence pool to bind to HBsAg protein. B: Enzymatic amplification of aptamers. RT-PCR: lane 1, DNA molecular weight marker; lane 2, PCR products in selex procedure. *In vitro* transcription: lane 1, RNA molecular weight marker. lane 2, Transcription products in selex procedure. C: Binding of RNA pools to HBsAg was increased with the ongoing selection process. Round 5, Round 6, Round 10, and Round 12 RNAs were ^{32}P-labeled and incubated with HBsAg, binding of ^{32}P-labeled RNAs were measured by Nitrocellulose filter-binding assay. D: Compelxes formation between RNA pools and HBsAg. ^{32}P-labeled nucleo-protein complexes were separated from unbound RNAs by native gel electrophoresis. lane 1, Round 12 RNAs + HBsAg; lane 2, Round 10 RNAs + HBsAg; lane 3, Round 6 RNAs + HBsAg; lane 4, Round 0 RNAs + HBsAg.

Fig. 3. Predicting secondary structures of round 12 aptamers. Over 90 percent of round 12 aptamers were represented by only two kinds of structures.

cloned. Twenty four randomly picked plasmid clones were sequenced. The secondary structures of these aptamers were predicted with RNA Structure Program version 4.6. The most stable structures with the lowest free energies for each RNA oligo were compared. Over 90% of round 12 aptamers were represented by only two kinds of structures (Fig. 3).

Aptamer inhibition of HBsAg reactivity

In order to rapidly determine the binding affinity of the aptamers, HBsAg reactivity inhibition assays were performed. The original random sequence library had almost no effect on inhibition of HBsAg reactivity, whereas the inhibition ablilities of RNA pools increased with the ongoing selection process. The inhibition abilities of aptamers with typical structures from two different structure families were also assayed. One aptamer, termed HBs-A22, was found to possess maximum inhibition (Fig. 4).

Cell-specific binding

Aptamer HBs-A22 was fluorescently labeled with FITC (HBs-A22-green) to evaluate if it could specifically bind to HBsAg-expressing liver cells. To increase


Fig. 4. Aptamer inhibition of HBsAg reactivity. The original random sequence pool had almost no effect on inhibition of HBsAg reactivity, whereas the inhibition ablilities of RNA pools increased with the ongoing selection process, and the final round RNA pool can almost totally inhibit the HBsAg reactivity. Aptamer HBs-A22 was found having maximum inhibition than all the other aptamers.

nuclease stability of the aptamer in serum, 2'-fluro-pyrimidines were incorporated during aptamer transcription. Fluorescence microscopy showed that HBs-A22-green specifically bound to the HBsAg- positive hepatoma cell lines HepG2.2.15, while no binding was shown to the HBsAg-negative cell line HepG2, suggesting that the cellular binding of the aptamer depends on the presence of HBsAg (Fig. 5).

Fig. 5. HepG2.2.15 cells staining by FITC-labeled aptamer HBs-A22-green specifically. Aptamer HBs-A22-green was incubated with HepG2.2.15 cells and HepG2 cells, the results were visualized by fluorescent microscopy. A: Aptamer H1-A25-green labels HBsAg-positive HepG2.2.15 cells. B: Aptamer HBs-A22-green shows no affinity for HBsAg-negative HepG2 cells.

DISCUSSION

Aptamers are non-naturally occurring structured oligonucleotides that may bind to small molecules, peptides, and proteins. Typically, aptamers are generated by an *in vitro* selection process referred to as SELEX. High-affinity aptamers against over 150 different targets including ATP[31], cytokines[25, 26], growth factors[23, 28], proteases[1, 29], immunoglobulins[36], and cell adhesion molecules[14, 35] have been reported. Recently, aptamers have received validation as a therapeutic modality with approval of the anti-VEGF aptamer pegaptanib for the treatment of wet age-related macular degeneration (AMD)[3, 20]. Aptamers that bind with high affinity and specificity to proteins that reside on the cell surface have potential utility as therapeutic antagonists, such as being used for cell-type specific delivery of siRNAs[5, 15, 19]. In brief, the history of applications suggests that aptamers may soon be an attractive alternative to antibodies for both *in vitro* and *in vivo* applications. Despite the success of


Fig. 6. Predicting secondary structure of aptamer HBs-A22. Nucleotides 23-47 of aptamer HBs-A22 (box) represented the sequences selected from randomized region of RNA library which can form a stem-loop structure.

SELEX, there are no reported RNA aptamers that bind to HBV related antigens.

During HBV replication, high levels of HBsAg are expressed on the surface of HBV-infected hepatocytes. HBsAg is sometimes considered a "tumour-associated antigen". While membrane- associated HBsAg provides a target for direct immune-mediated cytolysis, it also provides a good target for the specific delivery of anti-hepatitis B drugs [16, 30, 32].

Therefore, we used purified HBsAg protein as a target to select apamers with high specificity and affinity. Filter binding assays and gel shift assays were performed to determine the specificity and affinity of the selected aptamers. Two kinds of aptamers with different structures were identified from an initial RNA aptamer library of ~1.1×10^{15} sequences. The high affinity of these aptamers is demonstrated by their ability to inhibit HBsAg reactivity. One unique HBsAg-binding aptamer, HBs-A22, was found to bind to protein HBsAg with higher affinity than the others. The secondary structure of aptamer HBs-A22 was similar to most other aptamers in the twelfth pool, as the sequences of randomized regions of HBs-A22 can form a stem-loop structure, which may participate in binding with protein HBsAg (Fig. 6). We also found that fluorescence-tagged aptamer HBs-A22 can bind to HBsAg-positive hepatoma cell lines HepG2.2.15 with high specificity.

The work here describes the first application of SELEX to a HBV specific antigen and the first HBsAg aptamer. Additional modification of this high affinity aptamer toward even higher affinity and nuclease resistance should allow it to serve as a delivery vehicle for imaging, diagnostics, and therapeutic agents to the HBV related diseases.

References

1. **Bock L C, Griffin L C, Latham J A,** *et al*. 1992. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. **Nature,** 355 (6360): 564-566.

2. **Brody E N, Gold L.** 2000. Aptamers as therapeutic and diagnostic agents. **J Biotechnol,** 74 (1): 5-13.

3. **Chapman J A, Beckey C.** 2006. Pegaptanib: A novel approach to ocular neovascularization. **Ann Pharmacother,** 40 (7-8): 1322-1326.

4. **Chu C M, Liaw Y F.** 1987. Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection. Hepatocyte with cytoplasmic/membranous hepatitis B core antigen as a possible target for immune hepatocytolysis. **Gastroenterology,** 92: 220-225.

5. **Chu T C, Twu K Y, Ellington A D,** *et al*. 2006. Aptamer mediated siRNA delivery. **Nucleic Acids Res,** 34 (10): e73.

6. **Connell G J, Illangesekare M, Yarus M.** 1993. Three small ribooligonucleotides with specific arginine sites. **Biochemistry,** 1; 32 (21): 5497-502.

7. **Dienstag J L.** 2006. Looking to the future: new agents for chronic hepatitis B. **Am J Gastroenterol,** 101: S19-S25.

8. **Ellington A D, Szostak J W.** 1990. *In vitro* selection of RNA molecules that bind specific ligands. **Nature,** 30; 346 (6287): 818-822.

9. **Gish R G.** 2005. Current treatment and future directions in the management of chronic hepatitis B viral infection. **Clin Liver Dis,** 9: 541-565.

10. **Guan R.** 2005. Treatment of chronic hepatitis B infection using interferon. **Med J Malaysia,** 60: 28-33.

11. **Hicke B J, Marion C, Chang Y F,** *et al*. 2001. Tenascin-C aptamers are generated using tumor cells and purified protein. **J Biol Chem,** 28; 276 (52): 48644-48654.

12. **Hicke B J, Stephens A W.** 2000. Escort aptamers: a delivery service for diagnosis and therapy. **J Clin Invest,** 106 (8): 923-928.

13. **Jayasena S D.** 1999. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. **Clin Chem,** 45 (9): 1628-1650.

14. **Jenison R D, Jennings S D, Walker D W,** *et al.* 1998. Oligonucleotide inhibitors of P-selectin-dependent neutrophil-platelet adhesion, **Antisense Nucleic Acid Drug Dev,** 8 (4): 265-279.

15. **Khaled A, Guo S, Li F,** *et al.* 2005. Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology. **Nano Letters,** 5 (9): 1797-1808.

16. **Kojima T.** 1982. Immune electron microscopic study of hepatitis B virus associated antigens in hepatocytes. **Gastroenterol Jpn,** 17: 559-575.

17. **Liu C J, Liou J M, Chen D S,** *et al.* 2005. Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. **J Formos Med Assoc,** 104: 783-791.

18. **Marcellin P, Asselah T, Boyer N.** 2005. Treatment of chronic hepatitis B. **J Viral Hepat,** 12: 333-345.

19. **McNamara J O 2nd, Andrechek E R, Wang Y,** *et al.* 2006. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. **Nat Biotechnol,** 24 (8): 1005-1015.

20. **Ng E W, Shima D T, Calias P,** *et al.* 2006. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. **Nat Rev Drug Discov,** 5 (2): 123-132.

21. **Ocama P, Opio C K, Lee W M.** 2005. Hepatitis B virus infection: current status. **Am J Med,** 118: 1413.

22. **Onishi S, Saibara T, Ito K.** 1985. Hepatitis B surface antigen specific cytotoxic T lymphocyte activity in hepatitis B virus infection. **Gastroenterol Jpn,** 20: 330-337.

23. **Pagratis N C, Bell C, Chang Y F,** *et al.* 1997. Potent 2′-amino-, and 2′-fluoro-2′-deoxyribonucleotide RNA inhibitors of keratinocyte growth factor. **Nat Biotechnol,** 15 (1): 68-73.

24. **Perrillo R P.** 2005. Current treatment of chronic hepatitis B: benefits and limitations. **Semin Liver Dis,** 25: 20-28.

25. **Rhodes A, Deakin A, Spaull J,** *et al.* 2000. The generation and characterization of antagonist RNA aptamers to human oncostatin M. **J Biol Chem,** 275 (37): 28555-28561.

26. **Rhodes A, Smithers N, Chapman T,** *et al.* 2001. The generation and characterisation of antagonist RNA aptamers to MCP-1. **FEBS Lett,** 506 (2): 85-90.

27. **Rivkin A.** 2005. A review of entecavir in the treatment of chronic hepatitis B infection. **Curr Med Res Opin,** 21: 1845-1856.

28. **Ruckman J, Green L S, Beeson J,** *et al.* 1998. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. **J Biol Chem,** 273 (32): 20556-20567.

29. **Rusconi C P, Scardino E, Layzer J,** *et al.* RNA aptamers as reversible antagonists of coagulation factor IXa. **Nature.** 2002; 419 (6902): 90-94.

30. **Sasaki H, Kojima T, Matsui S,** *et al.* 1987. Interaction of lymphocytes with hepatocytes containing hepatitis B antigen: ultrastructural demonstration of target antigen and T-cell subsets by the peroxidase antibody technique. **Virchows Arch A Pathol Anat Histopathol,** 411: 489-498.

31. **Shu D, Guo P.** 2003. A viral RNA that binds ATP and contains a motif similar to an ATP-binding aptamer from SELEX. **J Biol Chem,** 278 (9): 7119-7125.

32. **Simon K, Lingappa V R, Ganem D.** 1988. Secreted hepatitis B surface antigen polypeptides are derived from a transmembrane precursor. **J Cell Biol,** 107: 2163-2168.

33. **Tian Y, Adya N, Wagner S,** *et al.* 1995. Dissecting protein:protein interactions between transcription factors with an RNA aptamer. **RNA,** 1 (3): 317-326.

34. **Tuerk C, Gold L.** 1990. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. **Science,** 3; 249 (4968): 505-510.

35. **Watson S R, Chang Y F, O'Connell D,** *et al.* 2000. Anti-L-selectin aptamers: binding characteristics, phar-macokinetic parameters, and activity against an intravascular target in vivo. **Antisense Nucleic Acid Drug Dev,** 10 (2): 63-75.

36. **Wiegand T W, Williams P B, Dreskin S C,** *et al.* 1996. High-affinity oligonucleotide ligands to human IgE inhibit binding to Fc epsilon receptor I. **J Immunol,** 157 (1): 221-230.

37. **Wright T L.** 2006. Introduction to chronic hepatitis B infection. **Am J Gastroenterol**, 101: S1-S6.